Results 91 to 100 of about 5,406 (200)

Enhanced efficacy of aprepitant-based triple prophylaxis in preventing postoperative nausea and vomiting following metabolic bariatric surgery: a single-center, retrospective cohort study

Frontiers in Medicine
BackgroundMetabolic bariatric surgery (MBS) is associated with high risk of postoperative nausea and vomiting (PONV). We aimed to investigate the impact of aprepitant-based triple prophylaxis on PONV after MBS.MethodsWe reviewed a retrospective cohort of
Xiaodong Shan, Xiaodong Shan, Xiaodong Shan, Yidi Yang, Xiaoao Xiao, Mingchuang Zhang, Rui Chen, Qingqiu Huang, Yuanqing Gao, Xitai Sun, Xitai Sun   +10 more
doaj   +1 more source

Aprepitant Restores Corneal Sensitivity and Reduces Pain in DED [PDF]

PURPOSE: This study aims to assess the efficacy of two aprepitant formulations (X1 and X2), in a preclinical model of dry eye disease (DED) induced by benzalkonium chloride (BAK).
Bonelli, Filippo, Lasagni Vitar, Romina Mayra, Fonteyne, Philippe, Demirsoy, Ibrahim Halil, Campestre, Fabiola, Ferrari, Giulio, Ferrari G., Campestre F., Fonteyne P., Bonelli F., Demirsoy I. H., Vitar R. M. L.   +11 more
core   +1 more source

Emesis control by aprepitant in children and adolescents with chemotherapy

, 2013
Background: Chemotherapy-induced nausea and vomiting (CINV) is a feared adverse reaction during cancer treatment. Aprepitant has shown to be effective for CINV in adults, but little is known on its effect in pediatrics.
Laureys, Genevieve, VERLOOY, JORIS, Benoit, Yves, Robays, Hugo, Bauters, Tieneke   +4 more
core   +1 more source

Is Aprepitant Effective in Preventing Postoperative Nausea and Vomiting? [PDF]

, 2016
OBJECTIVE: The objective of this selective EBM review is to determine whether or not aprepitant is effective in preventing postoperative nausea and vomiting.
Gomberg, Rebeccah M.
core   +1 more source

Antitumor Strategies Targeting Peptidergic Systems

Encyclopedia
Peptidergic systems show promise as targets for fighting tumors. While some peptides encourage the growth and spread of tumor cells and angiogenic mechanisms, others display antitumor properties. As such, peptide ligands and receptor antagonists could be
Francisco D. Rodríguez, Rafael Coveñas
doaj   +1 more source

Combined neurokinin-1 receptor antagonist and sorafenib is a promising approach for hepatocellular carcinoma therapy

Egyptian Liver Journal
Background HCC (Hepatocellular carcinoma) is the most common primary malignant cancer in the liver. Treatment options to incurable HCC such as sorafenib, an oral multikinase inhibitor, had numerous side effects and questionable effectiveness.
Heba E. Sedky, Yasmine N. Elwany, Eman S. El Alfy, Mona N. Elwany, Yasmin M. Nabil, Hazem F. Manna, Mohamed A. Abdelaziz, Wessam F. El Hadidy   +7 more
doaj   +1 more source

Chemotherapy-Induced Nausea and Vomiting: The Role of Aprepitant

, 2011
Antiemetics are given to cancer patients prior to their chemotherapy sessions to protect them from nausea and vomiting induced by chemotherapy. The responsible health care team member will choose the type of antiemetic required to prevent the patient ...
Muath Mohammed Abu Hilal
core  

Aprepitant [PDF]

, 2020
openaire   +1 more source

The efficacy of combination of ondansetron and aprepitant on preventing the radiotherapy-induced nausea and vomiting

Journal of Research in Medical Sciences, 2015
Background: Depending on the site of irradiation, about 40-80% of patients undergoing radiotherapy (RT) will experience nausea and/or vomiting. The current study aimed to investigate the efficacy of ondansetronas as a single agent and with a combination ...
Hamid Emami, Simin Hematti, Seyed Masoud Saeidian, Awat Feizi, Shahin Taheri, Pourya Adeli, Golshan Mahmoudi   +6 more
doaj  

Treatment-Requiring Postoperative Nausea and Vomiting in Ambulatory Oncology Surgery: Four-Year Trends in Antiemetic Utilization. [PDF]

Healthcare (Basel)
Hoffman J, Smith A, Massengill C, Nahrwold DA, Yang WW, Evans R.   +5 more
europepmc   +1 more source